Evaxion A/S
Every calculator, already run for EVAX
Open the full toolkit →You have the numbers on EVAX. Get the argument.
A written report on which of these readings actually decide the outcome for Evaxion A/S, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
4 analysts covering EVAXAnalyst Price Target Disagreement for Evaxion A/S
Wall Street's bull case implies +413% from the current price; the bear case implies +188%. A 224% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Evaxion A/S
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to targe…
EVAX — frequently asked
Is EVAX a buy right now?
Wall Street's consensus rating on Evaxion A/S is none across 4 analysts, with a mean price target of $11.25 (+261% vs. the current $3.12). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for Evaxion A/S?
Analysts covering Evaxion A/S (EVAX) range from a bear-case target of $9.00 to a bull-case high of $16.00, with a mean consensus target of $11.25 across 4 analysts. The spread of $7.00 (224% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Evaxion A/S against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Evaxion A/S
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full EVAX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Evaxion A/S, in minutes. 3 free reports included with every account — no credit card required.